3 results
To compare the effect of paclitaxel plus MORAb-003 to paclitaxel plus placebo on progression free survival (PFS) as determined by RECIST in subjects who are in a first platinum-resistant or refractory relapse of ovarian cancer.
The objective of this phase IIb is to compare the efficacy and safety of sorafenib to placebo of patients with ovarian epithelial or primary peritoneal cancers stage IIIb and IV who have achieved a complete clinical response after standard platinum/…
Primary Objective: * To make a preliminary assessment of the efficacy of a combined APR-246 and carboplatin/PLD chemotherapy regimen in patients with platinum sensitive recurrent HGSOC with mutated p53.Secondary Objective: * To assess the safety…